Design, synthesis, and biological evaluation of 1,5-benzothiazepine-4-one derivatives targeting factor VIIa/tissue factor.

[1]  Anamik Shah,et al.  1,5-Benzothiazepine, a versatile pharmacophore: a review. , 2008, European journal of medicinal chemistry.

[2]  S. Kadono,et al.  Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination. , 2008, Bioorganic & medicinal chemistry letters.

[3]  E. Nutescu,et al.  Rivaroxaban: an oral direct inhibitor of factor Xa. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  E. Nutescu,et al.  New anticoagulant agents: direct thrombin inhibitors. , 2008, Cardiology clinics.

[5]  N. Mackman.  Triggers, targets and treatments for thrombosis , 2008, Nature.

[6]  B. Clement,et al.  N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines. , 2007, Journal of medicinal chemistry.

[7]  R. A. Shirk,et al.  Inhibitors of Factor VIIa/Tissue Factor , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[8]  D. J. Garland,et al.  Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa. , 2007, Bioorganic & medicinal chemistry letters.

[9]  Y. Babu,et al.  Probing the S2 site of factor VIIa to generate potent and selective inhibitors: the structure of BCX-3607 in complex with tissue factor-factor VIIa. , 2007, Acta crystallographica. Section D, Biological crystallography.

[10]  A. Turpie.  Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[11]  B. Cosimelli,et al.  Diltiazem analogues: the last ten years on structure activity relationships. , 2007, Current medicinal chemistry.

[12]  U. Urleb,et al.  Recent advances in serine protease inhibitors as anticoagulant agents. , 2007, Current pharmaceutical design.

[13]  M. Okada,et al.  Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand. , 2006, Bioorganic & medicinal chemistry.

[14]  E. Gjerstad,et al.  Potent 4-amino-5-azaindole factor VIIa inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[15]  Liang Liu,et al.  Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability. , 2006, Bioorganic & medicinal chemistry letters.

[16]  B. Katz,et al.  Discovery of novel heterocyclic factor VIIa inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[17]  J. Janc,et al.  Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model. , 2006, Bioorganic & medicinal chemistry letters.

[18]  M. Adler,et al.  The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex--Part 2. , 2005, Bioorganic & medicinal chemistry letters.

[19]  A. Aubry,et al.  Structural elucidation of the β-turn inducing (S)-[3-amino-4-oxo-2,3-dihydro-5H-benzo[b][1,4]thiazepin-5-yl] acetic acid (DBT) motif , 2005 .

[20]  T. Kayahara,et al.  Optimization of a coagulation factor VIIa inhibitor found in factor Xa inhibitor library. , 2005, Bioorganic & medicinal chemistry.

[21]  L. Weber,et al.  Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[22]  S. Kadono,et al.  Crystal structure of human factor VIIa/tissue factor in complex with peptide mimetic inhibitor. , 2004, Biochemical and biophysical research communications.

[23]  D. Kirchhofer,et al.  Inhibitors of Tissue Factor. Factor VIIa for anticoagulant therapy. , 2004, Current medicinal chemistry.

[24]  H. Matter,et al.  Structure-based design of amidinophenylurea-derivatives for factor VIIa inhibition. , 2004, Bioorganic & medicinal chemistry letters.

[25]  R. Kurumbail,et al.  Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. , 2003, Journal of medicinal chemistry.

[26]  Eric Therrien,et al.  Targeting thrombin and factor VIIa: design, synthesis, and inhibitory activity of functionally relevant indolizidinones. , 2002, Bioorganic & medicinal chemistry letters.

[27]  Jean Martínez,et al.  AN IMPROVED SYNTHESIS OF (S)- OR (R)-N-BcE-PROTECTED 1,5-BENZOTHIAZEPINE DERIVATIVES , 2002 .

[28]  K. Inoguchi,et al.  Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. , 2001, Journal of medicinal chemistry.

[29]  E. Leahy,et al.  Optimization of a screening lead for factor VIIa/TF. , 2001, Bioorganic & medicinal chemistry letters.

[30]  M. Amblard,et al.  Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety. , 1999, Journal of medicinal chemistry.

[31]  D. Dubé,et al.  REDUCTIVE N-ALKYLATION OF AMIDES, CARBAMATES AND UREAS , 1999 .

[32]  J. Vacca,et al.  L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. , 1998, Bioorganic & medicinal chemistry letters.

[33]  A. Heitz,et al.  Synthesis of N- and side chain protected aspartyl and glutamyl aldehyde derivatives. Reinvestigation of the reduction of Weinreb amides , 1998 .

[34]  K. Kövér,et al.  Simple, Safe, Large Scale Synthesis of 5-Arylmethyl-2,2-dimethyl-1,3-dioxane-4,6-diones and 3-Arylpropanoic Acids , 1995 .

[35]  N. Trippodo,et al.  DUAL METALLOPROTEASE INHIBITORS. IV: UTILIZATION OF THIAZEPINES AND THIAZINES AS CONSTRAINED PEPTIDOMIMETIC SURROGATES IN MERCAPTOACYL DIPEPTIDES , 1994 .

[36]  P. Mui,et al.  elastase inhibitors containing conformationally restricted lactams as P3-P2 dipeptide replacements , 1993 .

[37]  M. Kori,et al.  Synthesis and angiotensin converting enzyme inhibitory activity of 1,5-benzothiazepine and 1,5-benzoxazepine derivatives. I. , 1986, Chemical & pharmaceutical bulletin.

[38]  J. Stanton,et al.  Angiotensin converting enzyme inhibitors: 1,5-benzothiazepine derivatives. , 1985, Journal of medicinal chemistry.

[39]  T. Nagao,et al.  Studies on a new 1,5-benzothiazepine derivative (CRD-401). IV. Coronary vasodilating effect and structure-activity relationship. , 1973, Chemical & pharmaceutical bulletin.

[40]  S. A. Harris,et al.  Hydrogenation of compounds containing divalent sulfur. , 1945, Journal of the American Chemical Society.